The group’s principal activities include developing and commercializing oral and injectable protein therapeutics. The products of the group include ALTU-135, ALTU-238, ALTU-237 and ALTU-236. The group operates from the United States. The revenue of the group for the year 2006 was $5,107 (Thousands)